ASRS 2020: Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD

Name: ASRS 2020: Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD
Uploaded: 2020-08-04T04:00:00.000Z
Description: Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."

August 4, 2020

Alex Delaney-Gesing

Video

Conference|ASRS

Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."

Justis P. Ehlers, MD, of the Cole Eye Institute at the Cleveland Clinic, speaks with Ophthalmology Times®' David Hutton on the key takeaways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)" during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

See more ASRS meeting coverage here